Home › Lung Cancer › California
Lung Cancer clinical trials in California
114 studies for Lung Cancer are looking for participants at sites in California.
Cities in California
- Los Angeles45 studies
- San Diego26 studies
- Baldwin Park23 studies
- San Francisco23 studies
- Sacramento23 studies
- Mountain View20 studies
- Irvine15 studies
- Orange15 studies
- Santa Monica14 studies
- Santa Rosa11 studies
- San Jose10 studies
- Roseville10 studies
- Vallejo10 studies
- Concord9 studies
- Long Beach8 studies
- Modesto8 studies
- Newport Beach7 studies
- San Bernardino7 studies
- Torrance7 studies
- Fremont7 studies
- Fresno7 studies
- Richmond7 studies
- Pleasanton6 studies
- San Mateo6 studies
- Oakland6 studies
- Santa Clara6 studies
- San Leandro5 studies
- Daly City5 studies
- Berkeley4 studies
- Burbank4 studies
- Stockton4 studies
- Glendale4 studies
- Sunnyvale4 studies
- Fullerton4 studies
- Anaheim4 studies
- Santa Barbara3 studies
- Upland3 studies
- Santa Maria3 studies
- Huntington Beach3 studies
- Riverside3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Sansum Clinic, Santa Barbara
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0497, Los Alamitos
- USC/Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07063745Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Tower Cancer Research Foundation, Beverly Hills
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- OPN Healthcare, Glendale
- MemorialCare Todd Cancer Institute, Long Beach
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07625644Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Sutter Auburn Faith Hospital, Auburn
- and 56 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- VA Palo Alto Health Care System, Palo Alto
Recruiting
Ages 50 to 80 · All sexes · Updated Nov 12, 2026 · NCT07168993Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- UCSF Cancer Center Burlingame, Burlingame
- Veterans Affairs Loma Linda Healthcare System, Loma Linda
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Nov 12, 2026 · NCT06096844A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Beverly Hills Cancer Center ( Site 0070), Beverly Hills
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06312137A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07099898Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
- City of Hope Medical Center, Duarte
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07664579Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- UC Irvine Health, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06881784The Vanguard Study: Testing a New Way to Screen for Cancer
- Kaiser Permanente-Division of Research, Pleasanton
- Naval Medical Center -San Diego, San Diego
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Oncura Health, Glendale
- UC San Diego Health - Moores Cancer Center, La Jolla
- California Research Institute, Los Angeles
- and 4 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
RecruitingEarly phase 1
Ages 22 and older · All sexes · Updated Nov 5, 2026 · NCT07235280A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Community Cancer Institute (CCI), Clovis
- Marin Cancer Care Inc, Greenbrae
- UCI Health-CIACC, Irvine
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- City of Hope, Duarte
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- and 22 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- UCSF Cancer Center Burlingame, Burlingame
- Kaiser Permanente Dublin, Dublin
- and 24 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT04181060A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Providence Medical Foundation (site 209), Santa Rosa
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0096, San Francisco
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07492680Distance-Based Exercise to Preserve Function and Prevent Disability
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- and 10 more
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Cedars-Sinai Medical Center, Los Angeles
- BASS Cancer Center, Walnut Creek
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06060613Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- John Muir Clinical Research Center, Concord
- University Of California - San Diego Moores Cancer Center, La Jolla
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06712316Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- St. Jude Medical Center, Fullerton
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Providence St. Joseph Hospital, Orange
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07185997Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- City of Hope National Medical Center, Duarte
- Hoag Memorial Hospital Presbyterian, Newport Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07499674Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06287775Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06014827Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- OPN Healthcare, Inc., Glendale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT05168566A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- VA Long Beach Healthcare System, Long Beach, CA, Long Beach
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles
Recruiting
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT02984761A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07154290Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Los Angeles
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Oct 21, 2026 · NCT05061550Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- University of California, Irvine, Irvine
- University of California Los Angeles, Los Angeles
- University of California at San Francisco, San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06582017From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.